Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol

Diabetes, Obesity and Metabolism

Volumn 5, Issue 2, 2003, Pages 131-135

  Valsamakis, G ^a   Chetty, R ^b   McTernan, P G ^a   Al Daghri, N M ^b   Barnett, A H ^a   Kumar, S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Adiponectin; Central obesity; Ethnicity; HDL cholesterol; Type 2 diabetes

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; ASIAN; BLOOD PRESSURE MEASUREMENT; BODY MASS; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ETHNOLOGY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; METABOLIC PARAMETERS; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RACE DIFFERENCE; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0344091550     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2003.00254.x     Document Type: Article

References (27)

1. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998; 6: 71s-82s.
2. Zimmet P, Boyko EJ, Collier GR, De Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999; 892: 25-44.
3. Kaplan NM. The deadly quartet. Upper body adiposity, glucose intolerance, hypertriglyceridaemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
4. Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ 1998; 316: 823-828.
5. Cappucio FP, Coog DG, Atkinson RW, Strazzulo P. Prevalence, detection and management of cardiovascular risk factors in different ethnic groups in South London. Heart 1997; 78: 555-563.
6. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332.
7. Hotamisligil GS. The role of TNF-a and TNF receptors in obesity and insulin resistance. J Int Med 1999; 245: 621-625.
8. Mohammed -Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1145-1158.
9. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
10. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
11. Berg AH, Du Combs TPX, Brownlee M, Scherer PE. The adipocyte secreted protein Acrp30 enhances hepatic insulin action. Nature Med 2001; 7: 947-953.
12. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
13. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. C-DNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
14. Berg AH, Combs TP, Scherer PH. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-89.
15. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipocyte-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
16. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipocyte derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
17. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte derived plasma protein, inhibits endothelial NF-kb signaling through a c-AMP-dependent pathway. Circulation 2000; 102: 1206-1301.
18. World Health Organization Expert Committee. Second report on diabetes mellitus. Technical Report Series 646. Geneva: WHO, 1980.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
21. U.S. Department of Health and Human Services. Public Health Service: ATP III guidelines at a glance: step 8 identify metabolic syndrome and treat. NIH Publication No: 01-3305, 2001.
22. Comuzzie AG, Funahashi T, Sonnenberg G et al. The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome. J Clin Endocrinol Metab 2001; 86: 4321-4325.
23. Ouchi N, Kihara S, Arita Y et al. Adipocyte derived plasma protein adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte derived macrophages. Circulation 2001; 103: 1057-1063.
24. Okamoto Y, Arita Y, Nishida M et al. An adipocyte-derived plasma protein adheres to injured vascular walls. Horm Metab Res 2000; 32: 47-50.
25. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165.
26. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinaemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinaemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
27. Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380.